• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Transl Med . Recurrent waning of anti-SARS-CoV-2 neutralizing antibodies despite multiple antigen encounters

tetano

Editor, Senior Moderator
J Transl Med


. 2025 Jul 11;23(1):783.
doi: 10.1186/s12967-025-06837-0. Recurrent waning of anti-SARS-CoV-2 neutralizing antibodies despite multiple antigen encounters

Edwards Pradenas[SUP] #[/SUP][SUP] 1 [/SUP], Victor Urrea[SUP] #[/SUP][SUP] 2 [/SUP], Silvia Marfil[SUP] 2 [/SUP], Tetyana Pidkova[SUP] 2 [/SUP], Carmen Aguilar-Gurrieri[SUP] 2 [/SUP], Ferran Abancó[SUP] 2 [/SUP], Lourdes Mateu[SUP] 3 4 [/SUP], Anna Chamorro[SUP] 3 [/SUP], Eulàlia Grau[SUP] 2 [/SUP], Macedonia Trigueros[SUP] 2 [/SUP], Jorge Carrillo[SUP] 2 [/SUP], Marta Massanella[SUP] 2 5 [/SUP], Benjamin Trinité[SUP] 2 [/SUP], Bonaventura Clotet[SUP] 2 3 4 [/SUP], Julià Blanco[SUP] 6 7 8 9 [/SUP]



Affiliations
Abstract

Background: SARS-CoV-2 neutralizing antibodies may protect against symptomatic infection in immunized individuals. However, vaccine-induced antibody levels wane over time, reducing vaccine efficacy. The definition of the waning kinetics of neutralizing SARS-CoV-2 responses and the potential impact of sequential antigen encounters are still poorly defined.
Methods: Plasma neutralizing activity was determined in longitudinally collected samples from SARS-CoV-2 infected, primo-vaccinated and boosted individuals. Neutralizing activity decay kinetics were modeled against time using Log-Log and biexponential models.
Results: Neutralizing antibody levels wane after an initial peak in all groups of vaccinated individuals with half-life ranging from 29 to 60 days. Exponential models showed a subsequent stabilization of neutralizing titers to a plateau. Both the peak response and the plateau values depended on vaccine type, infection status and severity of infection. Booster immunization by either vaccines or breakthrough infections did not modify peak, plateau or decay rate values.
Conclusions: Our results indicate that the waning of SARS-CoV-2 neutralizing antibody responses was recurrent even after several antigen encounters. Repeated immunizations would be required to maintain high levels of neutralizing antibodies and protect vulnerable individuals from symptomatic infection.

Keywords: Booster; Breakthrough infection; COVID-19; Humoral response; Hybrid immunity; Kinetics; Neutralization; Vaccine.

 
Back
Top Bottom